nimesulide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1935 51803-78-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nimesulide
  • mesulide
  • mesulid
  • nimsulid
  • sulidene
  • sulide
  • sulidan
  • Molecular weight: 308.31
  • Formula: C13H12N2O5S
  • CLOGP: 2.91
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 101.22
  • ALOGS: -4.23
  • ROTB: 4

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 9.27 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1985 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ductus arteriosus stenosis foetal 85.78 26.75 13 1923 158 50603030
Renal failure neonatal 84.76 26.75 13 1923 172 50603016
Drug abuse 79.97 26.75 41 1895 59805 50543383
Neonatal respiratory acidosis 71.40 26.75 11 1925 150 50603038
Cyanosis neonatal 58.64 26.75 10 1926 264 50602924
Bradycardia neonatal 53.18 26.75 11 1925 835 50602353
Neonatal respiratory distress syndrome 50.23 26.75 13 1923 2641 50600547
Gastritis erosive 41.74 26.75 13 1923 5121 50598067
Atrioventricular block complete 37.33 26.75 13 1923 7242 50595946
Contraindication to medical treatment 32.85 26.75 7 1929 613 50602575
Duplicate therapy error 32.74 26.75 5 1931 64 50603124
Product dispensing issue 31.30 26.75 5 1931 87 50603101
Tonsillar exudate 30.25 26.75 4 1932 16 50603172
Polyuria 29.98 26.75 11 1925 7110 50596078
Premature baby 28.66 26.75 14 1922 18323 50584865
Abdominal pain upper 27.34 26.75 32 1904 159277 50443911
Diabetic metabolic decompensation 26.79 26.75 7 1929 1473 50601715

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Body mass index abnormal 58.45 39.49 9 1069 129 29573320
Ligament calcification 54.25 39.49 9 1069 211 29573238
Confabulation 50.95 39.49 8 1070 131 29573318
Rash maculovesicular 45.88 39.49 6 1072 23 29573426
Palmoplantar pustulosis 45.28 39.49 7 1071 103 29573346
Ankylosing spondylitis 45.05 39.49 13 1065 4163 29569286
Lip erythema 43.66 39.49 6 1072 36 29573413
Negativism 43.02 39.49 8 1070 367 29573082
Sacroiliitis 39.58 39.49 9 1069 1118 29572331

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 93.27 23.10 65 3020 132309 64363338
Renal failure neonatal 84.94 23.10 12 3073 66 64495581
Ductus arteriosus stenosis foetal 84.79 23.10 12 3073 67 64495580
Neonatal respiratory acidosis 71.42 23.10 10 3075 51 64495596
Bradycardia neonatal 68.70 23.10 10 3075 70 64495577
Cyanosis neonatal 63.78 23.10 9 3076 49 64495598
Neonatal respiratory distress syndrome 57.85 23.10 10 3075 227 64495420
Gastritis erosive 52.26 23.10 19 3066 9576 64486071
Body mass index abnormal 51.83 23.10 9 3076 210 64495437
Ligament calcification 51.75 23.10 9 3076 212 64495435
Rash maculovesicular 43.65 23.10 6 3079 26 64495621
Premature baby 40.25 23.10 12 3073 3260 64492387
Confabulation 39.22 23.10 8 3077 451 64495196
Sacroiliitis 36.85 23.10 11 3074 3001 64492646
Negativism 35.20 23.10 8 3077 752 64494895
Lip erythema 33.82 23.10 6 3079 159 64495488
Erosive duodenitis 33.57 23.10 9 3076 1669 64493978
Palmoplantar pustulosis 32.83 23.10 7 3078 490 64495157
Foetal exposure during pregnancy 32.57 23.10 11 3074 4465 64491182
Face oedema 32.21 23.10 18 3067 24743 64470904
Spinal pain 30.65 23.10 14 3071 12607 64483040
Product dispensing issue 29.92 23.10 5 3080 92 64495555
Nasal mucosal disorder 29.49 23.10 6 3079 334 64495313
Tonsillar exudate 28.31 23.10 4 3081 22 64495625
Polyneuropathy in malignant disease 27.42 23.10 5 3080 155 64495492
Mixed liver injury 26.69 23.10 10 3075 5471 64490176
Low birth weight baby 26.52 23.10 6 3079 552 64495095
Duplicate therapy error 26.11 23.10 5 3080 203 64495444
Atrioventricular block complete 25.89 23.10 13 3072 14405 64481242
Genital ulceration 25.68 23.10 6 3079 637 64495010
Angioedema 25.17 23.10 22 3063 61799 64433848
Enanthema 24.83 23.10 6 3079 735 64494912
Intentional self-injury 24.53 23.10 16 3069 29028 64466619
Oral mucosa erosion 24.25 23.10 7 3078 1700 64493947
Liver injury 24.09 23.10 16 3069 29916 64465731
Contraindication to medical treatment 23.18 23.10 6 3079 972 64494675

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AX17 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Other antiinflammatory and antirheumatic agents, non-steroids
ATC M02AA26 MUSCULO-SKELETAL SYSTEM
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
Antiinflammatory preparations, non-steroids for topical use
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory agent
CHEBI has role CHEBI:50629 COX-2 inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.03 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostaglandin G/H synthase 2 Enzyme IC50 5.91 WOMBAT-PK
Prostaglandin G/H synthase 1 Enzyme IC50 5.42 CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 4.93 DRUG MATRIX
Aromatase Enzyme IC50 4.57 WOMBAT-PK
cAMP-specific 3',5'-cyclic phosphodiesterase 4A Enzyme IC50 5.70 WOMBAT-PK
Myeloperoxidase Enzyme IC50 5.68 CHEMBL
Interstitial collagenase Enzyme IC50 4.63 DRUG MATRIX
Prostaglandin G/H synthase 1 Enzyme IC50 5.21 CHEMBL
Prostaglandin G/H synthase 2 Enzyme IC50 6.40 CHEMBL
Sodium-dependent neutral amino acid transporter B(0)AT1 Transporter INHIBITOR IC50 4.64 IUPHAR
Dipeptidyl peptidase 3 Enzyme Ki 4.16 CHEMBL

External reference:

IDSource
D01049 KEGG_DRUG
C0132515 UMLSCUI
CHEBI:44445 CHEBI
NIM PDB_CHEM_ID
CHEMBL56367 ChEMBL_ID
DB04743 DRUGBANK_ID
C012655 MESH_SUPPLEMENTAL_RECORD_UI
4495 PUBCHEM_CID
7401 IUPHAR_LIGAND_ID
4885 INN_ID
V4TKW1454M UNII
53694 RXNORM
004182 NDDF
703479000 SNOMEDCT_US
703480002 SNOMEDCT_US

Pharmaceutical products:

None